Recent Dealmaking (04/2004)
Summarizing the month in European dealmaking.
You may also be interested in...
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.
Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”
In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.